Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Varicella Vaccine at Various Potencies Compared With Varivax, as a First Dose, Administered in Healthy Children in Their Second Year of Life

NCT05084508 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05084508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05084508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Varicella Vaccine at Various Potencies Compared With Varivax, as a First Dose, Administered in Healthy Children in Their Second Year of Life
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
February 3, 2022
Completion date
June 13, 2024
Enrollment
800 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

chickenpox